Bio Pharma Dive
MAY 2, 2024
The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.
Pharmaceutical Technology
MAY 2, 2024
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MAY 2, 2024
Delphia is developing medicines designed to overstress certain cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.
Pharmaceutical Technology
MAY 2, 2024
Xyphos Biosciences and Poseida Therapeutics have signed a deal to develop new allogeneic cell therapies for treating cancer.
Bio Pharma Dive
MAY 2, 2024
The $1 billion dollar acquisition will add to Novartis’ pipeline of the targeted radiation drugs, giving it a potential lung cancer treatment.
Pharmaceutical Technology
MAY 2, 2024
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
MAY 2, 2024
Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 2, 2024
In a concerted effort to fortify regulatory capabilities and enhance pharmaceutical exports, the Central Drugs Standard Control Organisation (CDSCO) has orchestrated a series of impactful training initiatives in the fiscal year 2023-24.
Bio Pharma Dive
MAY 2, 2024
First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.
Pharmaceutical Technology
MAY 2, 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry involving companies developing drugs showed a 20% increase in total deal volume in the first quarter (Q1) of 2024 compared to Q1 2023, according to leading data and analytics company GlobalData’s Pharma Intelligence Center Deals Database.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
MAY 2, 2024
The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.
Pharmaceutical Technology
MAY 2, 2024
Discover how MacroGenics Inc's patent for compounds targeting IL23A and BAFF offers a groundbreaking method for suppressing inflammatory responses. Learn about the specific polypeptide compositions and nucleic acids involved.
pharmaphorum
MAY 2, 2024
Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s podcast with Zach Powers, chief information security officer at Benchling, the R&D cloud platform for the biotech industry.
Pharmaceutical Technology
MAY 2, 2024
Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
MAY 2, 2024
The updated ICH E6(R3) Good Clinical Practice guidelines are here - discover what's changed and how clinical trials will need to adapt. This in-depth post unravels the key impacts of E6(R3).
Pharmaceutical Technology
MAY 2, 2024
Discover Astellas Pharma's patented carbocyclic prolinamide derivatives for treating eye diseases like macular degeneration. Explore the unique compound structure and potential applications in pharmaceuticals and beyond.
pharmaphorum
MAY 2, 2024
Pursue your passion for science with a rewarding career in life sciences. Learn how a job in biology, biotech, or health sciences offers intellectual stimulation and the chance to improve lives.
Pharmaceutical Technology
MAY 2, 2024
Discover Vertex Pharmaceuticals' groundbreaking patent for compounds treating alpha-1 antitrypsin deficiency. Explore formula (I) derivatives and tailored compositions for precision medicine.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
MAY 2, 2024
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug. | Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug.
Pharmaceutical Technology
MAY 2, 2024
Discover how BioCryst Pharmaceuticals' patent for complement system inhibitors offers groundbreaking treatment options for various diseases.
XTalks
MAY 2, 2024
The 18th Annual Canadian Summit on Food Safety , held last week, brought together industry leaders, regulatory experts and innovators to discuss the current state and future of food safety. The event spanned two days packed with keynote speeches, panel discussions and networking opportunities aimed at enhancing food safety practices across the country.
Pharmaceutical Technology
MAY 2, 2024
As the obesity space becomes more congested, clinical trial recruitment has become a larger issue for small biotechs.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Fierce Pharma
MAY 2, 2024
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday. In turn, the company is eyeing a potential U.S. launch in the fall, which would capitalize on its established commercial efforts in the seasonal COVID-19 immuni
Pharmaceutical Technology
MAY 2, 2024
The US FDA has granted approval to Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable biosimilar to Humira (adalimumab).
Fierce Pharma
MAY 2, 2024
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a unique win in previously untreated mantle cell lymphoma (MCL). | AstraZeneca is touting a earlier-than-expected positive readout for Calquence in first-line mantle cell lymphoma. But a big question remains whether it can immediately file with the FDA, especially given the precedent of Imbruvica.
Pharmaceutical Technology
MAY 2, 2024
Janssen-Cilag has sought expanded European Medicines Agency (EMA) approval for TREMFYA to treat active ulcerative colitis and Crohn’s disease.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MAY 2, 2024
A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.
Pharmaceutical Technology
MAY 2, 2024
Pfizer’s reported net income stood at $3.11bn in Q1 2024, marking a decrease of 44% from $5.54bn posted in the same period of 2023.
pharmaphorum
MAY 2, 2024
Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries.
Pharmaceutical Technology
MAY 2, 2024
Emerging research from the ESCMID Global 2024 conference suggests that antifungal resistance, a global issue, is on the rise.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
300 
Let's personalize your content